CR20130293A - Composiciones terapéuticas que comprenden rilpivirina hcl y tenofovir disoproxil fumarato - Google Patents

Composiciones terapéuticas que comprenden rilpivirina hcl y tenofovir disoproxil fumarato

Info

Publication number: CR20130293A
Authority: CR; Costa Rica
Prior art keywords: disoproxil fumarate; therapeutic compositions; tenofovir disoproxil; rilpivirine hcl; include rilpivirine
Prior art date: 2010-11-19

Application number

CR20130293A

Other languages

English (en)

Inventor

Reza Oliyai

Lauren Wiser

Mark Menning

Original Assignee

Gilead Sciences Inc

Janssen R & D Ireland

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-11-19

Filing date

2013-06-17

Publication date

2013-10-03

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45094284&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20130293(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-06-17 Application filed by Gilead Sciences Inc, Janssen R & D Ireland filed Critical Gilead Sciences Inc

2013-10-03 Publication of CR20130293A publication Critical patent/CR20130293A/es

Links

239000000203 mixture Substances 0.000 title 1
229960002814 rilpivirine Drugs 0.000 title 1
YIBOMRUWOWDFLG-ONEGZZNKSA-N rilpivirine Chemical compound CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 YIBOMRUWOWDFLG-ONEGZZNKSA-N 0.000 title 1
229960004693 tenofovir disoproxil fumarate Drugs 0.000 title 1
VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 title 1
230000001225 therapeutic effect Effects 0.000 title 1
XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 abstract 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 abstract 1
229960000366 emtricitabine Drugs 0.000 abstract 1
229960004481 rilpivirine hydrochloride Drugs 0.000 abstract 1
KZVVGZKAVZUACK-BJILWQEISA-N rilpivirine hydrochloride Chemical compound Cl.CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 KZVVGZKAVZUACK-BJILWQEISA-N 0.000 abstract 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

CR20130293A 2010-11-19 2013-06-17 Composiciones terapéuticas que comprenden rilpivirina hcl y tenofovir disoproxil fumarato CR20130293A (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US41560010P	2010-11-19	2010-11-19

Publications (1)

Publication Number	Publication Date
CR20130293A true CR20130293A (es)	2013-10-03

Family

ID=45094284

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CR20130293A CR20130293A (es)	2010-11-19	2013-06-17	Composiciones terapéuticas que comprenden rilpivirina hcl y tenofovir disoproxil fumarato

Country Status (36)

Country	Link
US (1)	US10857102B2 (es)
EP (2)	EP2640362B2 (es)
JP (2)	JP2014500261A (es)
KR (1)	KR101923103B1 (es)
CN (2)	CN106511357A (es)
AP (1)	AP3816A (es)
AR (2)	AR084500A1 (es)
AU (3)	AU2011329642B2 (es)
BR (1)	BR112013012245B1 (es)
CA (1)	CA2818097C (es)
CL (1)	CL2013001402A1 (es)
CO (1)	CO6761300A2 (es)
CR (1)	CR20130293A (es)
DK (1)	DK2640362T4 (es)
EA (2)	EA201691695A1 (es)
EC (2)	ECSP13012700A (es)
ES (1)	ES2524408T5 (es)
HK (1)	HK1206592A1 (es)
HR (1)	HRP20140946T1 (es)
IL (1)	IL226300B (es)
MA (1)	MA34735B1 (es)
ME (1)	ME01980B (es)
MX (1)	MX347512B (es)
MY (1)	MY185604A (es)
NZ (1)	NZ610729A (es)
PE (3)	PE20211657A1 (es)
PH (1)	PH12013501002A1 (es)
PL (1)	PL2640362T5 (es)
PT (1)	PT2640362E (es)
RS (1)	RS53691B1 (es)
SG (3)	SG190333A1 (es)
SM (1)	SMT201400150B (es)
TW (1)	TWI556840B (es)
UA (1)	UA114075C2 (es)
WO (1)	WO2012068535A1 (es)
ZA (1)	ZA201304481B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT1583542E (pt)	2003-01-14	2008-09-17	Gilead Sciences Inc	Composições e métodos para terapia de combinação antiviral
TWI471145B (zh)	2005-06-13	2015-02-01	Bristol Myers Squibb & Gilead Sciences Llc	單一式藥學劑量型
NZ610729A (en)	2010-11-19	2015-10-30	Gilead Sciences Inc	Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate
AP3639A (en)	2011-08-16	2016-03-13	Gilead Sciences Inc	Tenofovir alafenamide hemifumarate
CA2779052A1 (en) *	2012-05-31	2013-11-30	Pharmascience Inc.	Pharmaceutical composition of entecavir and process of manufacturing
EA030003B1 (ru)	2012-12-21	2018-06-29	Джилид Сайэнс, Инк.	Полициклическое карбамоилпиридоновое соединение и его фармацевтическое применение для лечения вич-инфекции
EP2832351A1 (en) *	2013-07-29	2015-02-04	Sanovel Ilac Sanayi ve Ticaret A.S.	Multilayer Tablet Formulations Comprising Tenofovir and Entecavir
CZ2013985A3 (cs) *	2013-12-09	2015-06-17	Zentiva, K.S.	Stabilní farmaceutická kompozice obsahující tenofovir disoproxil fumarát
WO2015152433A1 (en) *	2014-03-31	2015-10-08	Hanmi Pharm. Co., Ltd.	Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same
WO2016106050A1 (en)	2014-12-26	2016-06-30	Emory University	N4-hydroxycytidine and derivatives and anti-viral uses related thereto
US9839212B2 (en)	2015-04-16	2017-12-12	Bio-Lab, Inc.	Multicomponent and multilayer compacted tablets
CA2921336A1 (en) *	2015-06-30	2016-12-30	Gilead Sciences, Inc.	Pharmaceutical formulations
KR20170003063A (ko) *	2015-06-30	2017-01-09	한미약품 주식회사	테노포비어 디소프록실 함유 경구용 고형제제 및 그 제조방법
EP4233846B1 (en)	2015-06-30	2024-12-04	Gilead Sciences, Inc.	Pharmaceutical formulations
CN113546052A (zh)	2015-11-09	2021-10-26	吉利德科学公司	治疗人免疫缺陷病毒的治疗组合物
WO2017175855A1 (en) *	2016-04-08	2017-10-12	Shionogi & Co., Ltd.	Stabilized solid dosage form
TR201617448A2 (tr) *	2016-11-29	2018-06-21	Arven Ilac Sanayi Ve Ticaret Anonim Sirketi	Tenofovi̇r ve emtri̇si̇tabi̇n i̇çeren kati oral farmasöti̇k bi̇leşi̇mler
US10561614B2 (en) *	2017-01-27	2020-02-18	Steerlife India Private Limited	Tenofovir granules
RU2755710C2 (ru) *	2017-06-30	2021-09-20	Вайв Хелткер Компани	Комбинация, ее применение и способы лечения с использованием указанной комбинации
RU2020116571A (ru)	2017-12-07	2021-11-22	Эмори Юниверсити	N4-гидроксицитидин и производные и связанные с этим противовирусные применения
MA56449A (fr) *	2019-07-03	2022-05-11	Janssen Sciences Ireland Unlimited Co	Procédés de traitement du vih chez des patients pédiatriques par la rilpivirine
CN112137981A (zh) *	2020-11-02	2020-12-29	成都晶富医药科技有限公司	富马酸丙酚替诺福韦片及其制备工艺
WO2024211882A1 (en) *	2023-04-07	2024-10-10	Navinta, Llc	Stable compositions of rilpivirine hcl in combination with other anti-retroviral agents
CN119174735A (zh) *	2024-09-03	2024-12-24	安徽贝克生物制药有限公司	一种含利匹韦林的复方片及制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL100965A (en)	1991-02-22	1999-12-31	Univ Emory	2-Hydroxymethyl-5-(5-fluorocytosin-l-yl)-1,3-oxathiolane its resolution and pharmaceutical compositions containing it
MY169670A (en) *	2003-09-03	2019-05-08	Tibotec Pharm Ltd	Combinations of a pyrimidine containing nnrti with rt inhibitors
JO3429B1 (ar)	2001-08-13	2019-10-20	Janssen Pharmaceutica Nv	مشتقات برميدينات مثبطة فيروس الايدز
AU2002359518A1 (en)	2001-11-27	2003-06-10	Bristol-Myers Squibb Company	Efavirenz tablet formulation having unique biopharmaceutical characteristics
PT1583542E (pt)	2003-01-14	2008-09-17	Gilead Sciences Inc	Composições e métodos para terapia de combinação antiviral
PT1632232E (pt)	2004-09-02	2011-08-02	Janssen Pharmaceutica Nv	Sal de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]- 2-pirimidinil]amino]benzonitrilo
CA2577288C (en)	2004-09-02	2010-11-30	Janssen Pharmaceutica N.V.	Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
TWI375560B (en) *	2005-06-13	2012-11-01	Gilead Sciences Inc	Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) *	2005-06-13	2015-02-01	Bristol Myers Squibb & Gilead Sciences Llc	單一式藥學劑量型
EP1933815A2 (en)	2005-10-14	2008-06-25	Microdose Technologies Inc.	Pharmaceutical packaging of an oral dosage combination
ATE474560T1 (de)	2005-12-14	2010-08-15	Cipla Ltd	Pharmazeutische kombination aus nucleotid und nucleosid-reverse-transkriptase-hemmern (wie tenofovir und lamivudin) in verschiedenen teilen der dosiereinheit
PT3150586T (pt) *	2007-02-23	2020-03-31	Gilead Sciences Inc	Moduladores de propriedades farmacocinéticas de agentes terapêuticos
US20080286344A1 (en)	2007-05-16	2008-11-20	Olivia Darmuzey	Solid form
WO2008140461A1 (en)	2007-05-16	2008-11-20	Fmc Corporation	Solid form
EP2160394A1 (en)	2007-05-22	2010-03-10	Ultimorphix Technologies B.v.	Tenofovir disoproxil hemi-fumaric acid co-crystal
WO2009037449A1 (en)	2007-09-18	2009-03-26	Cipla Limited	Solid pharmaceutical compositions comprising one or more herpes virus inhibitors and one or more reverse transcriptase inhibitors
WO2009106960A2 (en)	2008-02-27	2009-09-03	Aurobindo Pharma Limited	Stable compositions of lamivudine, tenofovir and efavirenz
EA201591353A1 (ru)	2008-05-02	2016-01-29	Джилид Сайэнс, Инк.	Применение частиц твердого носителя для улучшения технологических характеристик фармацевтического агента
PL2393485T3 (pl)	2009-02-06	2015-12-31	Gilead Sciences Inc	Dwuwarstwowe tabletki zawierające elwitegrawir, kobicystat, emtrycytabinę i tenofowir
DK2480552T3 (en)	2009-09-21	2017-02-20	Gilead Sciences Inc	2 'FLUOROUS-SUBSTITUTED CARBA NUCLEOSIDE ANALYSIS FOR ANTIVIRAL TREATMENT
WO2011077100A1 (en)	2009-12-24	2011-06-30	Cipla Limited	Antiretroviral composition
NZ610729A (en)	2010-11-19	2015-10-30	Gilead Sciences Inc	Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate

2011
- 2011-11-18 NZ NZ610729A patent/NZ610729A/en unknown
- 2011-11-18 EP EP11791161.0A patent/EP2640362B2/en active Active
- 2011-11-18 WO PCT/US2011/061515 patent/WO2012068535A1/en not_active Ceased
- 2011-11-18 JP JP2013540085A patent/JP2014500261A/ja not_active Withdrawn
- 2011-11-18 ME MEP-2014-150A patent/ME01980B/me unknown
- 2011-11-18 PE PE2021000720A patent/PE20211657A1/es unknown
- 2011-11-18 AU AU2011329642A patent/AU2011329642B2/en active Active
- 2011-11-18 CN CN201610900183.1A patent/CN106511357A/zh active Pending
- 2011-11-18 US US13/988,072 patent/US10857102B2/en active Active
- 2011-11-18 PH PH1/2013/501002A patent/PH12013501002A1/en unknown
- 2011-11-18 MX MX2013005669A patent/MX347512B/es active IP Right Grant
- 2011-11-18 AR ARP110104318A patent/AR084500A1/es not_active Application Discontinuation
- 2011-11-18 PT PT117911610T patent/PT2640362E/pt unknown
- 2011-11-18 MY MYPI2016001764A patent/MY185604A/en unknown
- 2011-11-18 SG SG2013038484A patent/SG190333A1/en unknown
- 2011-11-18 TW TW100142311A patent/TWI556840B/zh active
- 2011-11-18 KR KR1020137015719A patent/KR101923103B1/ko active Active
- 2011-11-18 PE PE2013001214A patent/PE20140163A1/es not_active Application Discontinuation
- 2011-11-18 AP AP2013006931A patent/AP3816A/en active
- 2011-11-18 EP EP14183494.5A patent/EP2826466A1/en not_active Withdrawn
- 2011-11-18 BR BR112013012245-5A patent/BR112013012245B1/pt active IP Right Grant
- 2011-11-18 RS RS20140668A patent/RS53691B1/sr unknown
- 2011-11-18 EA EA201691695A patent/EA201691695A1/ru unknown
- 2011-11-18 UA UAA201306403A patent/UA114075C2/uk unknown
- 2011-11-18 CA CA2818097A patent/CA2818097C/en active Active
- 2011-11-18 ES ES11791161T patent/ES2524408T5/es active Active
- 2011-11-18 PL PL11791161T patent/PL2640362T5/pl unknown
- 2011-11-18 CN CN201180063666.6A patent/CN103491948B/zh active Active
- 2011-11-18 EA EA201390651A patent/EA025852B1/ru unknown
- 2011-11-18 SG SG10201509521WA patent/SG10201509521WA/en unknown
- 2011-11-18 SG SG10201912527XA patent/SG10201912527XA/en unknown
- 2011-11-18 PE PE2016002828A patent/PE20170521A1/es unknown
- 2011-11-18 HR HRP20140946AT patent/HRP20140946T1/hr unknown
- 2011-11-18 DK DK11791161.0T patent/DK2640362T4/da active
2013
- 2013-05-12 IL IL226300A patent/IL226300B/en active IP Right Grant
- 2013-05-17 CL CL2013001402A patent/CL2013001402A1/es unknown
- 2013-05-28 CO CO13130615A patent/CO6761300A2/es unknown
- 2013-06-14 MA MA36010A patent/MA34735B1/fr unknown
- 2013-06-17 CR CR20130293A patent/CR20130293A/es unknown
- 2013-06-18 EC ECSP13012700 patent/ECSP13012700A/es unknown
- 2013-06-18 ZA ZA2013/04481A patent/ZA201304481B/en unknown
2014
- 2014-03-21 HK HK15106347.0A patent/HK1206592A1/en unknown
- 2014-10-16 SM SM201400150T patent/SMT201400150B/xx unknown
2015
- 2015-04-20 JP JP2015085594A patent/JP6138851B2/ja active Active
2016
- 2016-07-29 AU AU2016208417A patent/AU2016208417B2/en active Active
2018
- 2018-04-16 AU AU2018202635A patent/AU2018202635A1/en not_active Abandoned
2019
- 2019-10-30 EC ECSENADI201978196A patent/ECSP19078196A/es unknown
2020
- 2020-11-19 AR ARP200103214A patent/AR123409A2/es unknown

Also Published As

Publication number	Publication date
ES2524408T5 (es)	2022-04-25
PH12013501002A1 (en)	2013-09-09
AU2011329642B2 (en)	2016-08-11
CN106511357A (zh)	2017-03-22
CL2013001402A1 (es)	2013-12-27
TW201238612A (en)	2012-10-01
DK2640362T3 (en)	2014-12-01
AU2018202635A1 (en)	2018-05-10
HK1190064A1 (en)	2014-06-27
AP3816A (en)	2016-09-30
SMT201400150B (it)	2015-01-15
MX2013005669A (es)	2013-11-04
PL2640362T3 (pl)	2015-03-31
PE20140163A1 (es)	2014-02-08
SG190333A1 (en)	2013-06-28
EA025852B1 (ru)	2017-02-28
PL2640362T5 (pl)	2022-05-02
JP6138851B2 (ja)	2017-05-31
ME01980B (me)	2015-05-20
EA201691695A1 (ru)	2017-11-30
US10857102B2 (en)	2020-12-08
HK1206592A1 (en)	2016-01-15
EP2640362B1 (en)	2014-09-10
UA114075C2 (xx)	2017-04-25
KR101923103B1 (ko)	2018-11-28
AU2011329642A1 (en)	2013-05-02
RS53691B1 (sr)	2015-04-30
MA34735B1 (fr)	2013-12-03
US20130243857A1 (en)	2013-09-19
AU2016208417B2 (en)	2018-04-05
EA201390651A1 (ru)	2013-11-29
AR084500A1 (es)	2013-05-22
AP2013006931A0 (en)	2013-06-30
KR20140037799A (ko)	2014-03-27
PT2640362E (pt)	2014-11-28
MX347512B (es)	2017-04-28
ECSP13012700A (es)	2013-08-30
AR123409A2 (es)	2022-11-30
CO6761300A2 (es)	2013-09-30
SG10201912527XA (en)	2020-02-27
JP2014500261A (ja)	2014-01-09
PE20211657A1 (es)	2021-08-24
MY185604A (en)	2021-05-25
BR112013012245A2 (pt)	2016-08-09
IL226300B (en)	2019-05-30
TWI556840B (zh)	2016-11-11
ES2524408T3 (es)	2014-12-09
BR112013012245B1 (pt)	2022-09-27
EP2640362B2 (en)	2021-12-01
CA2818097C (en)	2019-07-30
CN103491948A (zh)	2014-01-01
CN103491948B (zh)	2016-11-02
ZA201304481B (en)	2022-03-30
NZ610729A (en)	2015-10-30
PE20170521A1 (es)	2017-05-27
EP2826466A1 (en)	2015-01-21
HRP20140946T1 (hr)	2015-02-13
JP2015131853A (ja)	2015-07-23
DK2640362T4 (da)	2022-03-07
ECSP19078196A (es)	2019-11-30
SG10201509521WA (en)	2015-12-30
WO2012068535A1 (en)	2012-05-24
CA2818097A1 (en)	2012-05-24
AU2016208417A1 (en)	2016-08-18
EP2640362A1 (en)	2013-09-25

Publication	Publication Date	Title
ECSP19078196A (es)	2019-11-30	Composiciones terapéuticas que comprenden rilpivirina hcl y tenofovir disoproxil fumarato
PH12017502431A1 (en)	2018-07-02	Pharmaceutical formulations comprising tenofovir and emtrictabine
NZ738524A (en)	2019-02-22	Pharmaceutical formulations comprising rilpivirine hydrochloride, tenofovir alafenamide hemifumarate, and emtricitabine
ECSP12011585A (es)	2012-02-29	Compuestos y composiciones para eltratamiento de enfermedades parasitarias
IN2014DN10670A (es)	2015-08-28
EA201201263A1 (ru)	2013-04-30	Фармацевтическая композиция, содержащая этексилат дабигатрана
MY191357A (en)	2022-06-19	Sustained-release dosage forms of ruxolitinib
EA202092456A2 (ru)	2021-05-31	Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака
UA115311C2 (uk)	2017-10-25	Геміфумарат тенофовіру алафенаміду
ATE530170T1 (de)	2011-11-15	Paliperidonformulierung mit verzögerter freisetzung
MX378726B (es)	2025-03-11	Uso de compuestos de tiazolida para la prevencion y tratamiento de enfermedades virales, cancer y enfermedades causadas por infecciones intracelulares.
CY1121999T1 (el)	2020-07-31	Φαρμακοτεχνικες μορφες συνδυασμου δαρουναβιρης
EP3513789A3 (en)	2019-09-25	Prophylactic and therapeutic agents for fgfr3 diseases
CY1118074T1 (el)	2017-06-28	Ανθελονοσιακοι παραγοντες
MX374931B (es)	2025-03-06	Composiciones farmaceuticas que contienen doravirina, tenofovir disoproxil fumarato y lamivudina.
MX2015013755A (es)	2016-05-31	Formulacion farmaceutica para uso en el tratamiento y/o prevencion de restenosis.
CY1118255T1 (el)	2017-06-28	Υποκατεστημενα 6-αμινο-νικοτιναμιδια τα οποια φερουν μια ομαδα που περιεχει οη ως διαμορφωτες των kcnq2/3
TR201100151A2 (tr)	2012-07-23	İbandronate formülasyonu.
CY1116115T1 (el)	2017-02-08	Θεραπευτικες συνθεσεις οι οποιες αποτελουνται απο ριλπιβιρινη hcl και δισοπροξιλικη φουμαρικη τενοφοβιρη
TH171908A (th)	2017-12-28	องค์ประกอบบำบัดที่ประกอบรวมด้วย ริลพิวิรีน HCL (rilpivirine HCL) และ เทโนโฟเวียร์ ไดโซพรอกซิล ฟิวมาเรต (tenofovir disoproxil fumarate)
TR201200215A2 (tr)	2012-07-23	Geliştirilmiş farmasötik formülasyonlar.
CY1115356T1 (el)	2017-01-04	Συντηγμeνες ιμιδαζολες και συνθεσεις περιλαμβανοντας αυτες για την αγωγη παρασιτικων παθησεων, οπως ειναι π.χ. η ελονοσια
TR201200212A2 (tr)	2012-07-23	Risedronat içeren geliştirilmiş formülasyonlar.